TUCSON, Ariz., May 8, 2025 — The year 2025 marks a historic milestone for Critical Path Institute® (C-Path), as the organization celebrates 20 years of transforming the landscape of drug development through collaboration, regulatory science, and next-generation strategies. Continue reading
Category Archives: AZBio News
Castle Biosciences to Acquire Previse
Expected to complement Castle’s current gastroenterology franchise
Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in developmentContinue reading
PREVAIL Act Reintroduced The PREVAIL Act to Address
The Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act supports American inventors, encourages investments in intellectual property, secures U.S. global technology leadership, and safeguards both economic and national security.
“The PREVAIL Act will empower startups and small businesses by realigning the Patent Trial and Appeals Board with Congress’s original intent,” — Dr. Hans Sauer, Deputy General Counsel and Vice President for Intellectual Property, Biotechnology Innovation Organization (BIO).
CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics
Latest Series A3 financing includes Labcorp, along with new and longtime investorsContinue reading
NIH to prioritize human-based research technologies
New initiative aims to reduce use of animals in NIH-funded research.Continue reading
AdvaMed CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners
WASHINGTON, – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for medical technologies. In an interview with Joe Mullings of the Mullings Group, Whitaker stated that tariff-free trade is critical to maintaining the highly competitive nature of the medtech industry, which keeps prices down and serves patients nationwide and globally with a robust breadth and depth of lifesaving medtech. Continue reading
First-of-Its-Kind Cancer Therapy Targets ‘Undruggable’ Protein Interaction
A groundbreaking cancer therapy being developed in Phoenix is rewriting the rules of drug discovery by targeting what scientists have long considered “undruggable”— a critical interaction between two proteins that drive tumor growth and spreadingContinue reading
NSF Director Sethuraman Panchanathan Resigns
Dr. Sethuraman “Panch” Panchanathan announced on April 24, 2025 his decision to “step down as Director of the U.S. National Science Foundation (NSF), effective today.” He was in the fifth year of his six year appointment.
Arizona’s Bioscience Roadmap 2025 Progress Update
On April 23, 2025, the Flinn Foundation releases this year’s Progress Report on Arizona’s Bioscience Roadmap included new data on bioscience performance metrics from TEConomy Partners, an update on the University of Arizona’s strategic directions, and a look at the new Roadmap from SRI International.
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
- USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and an additional site location to be announced soon
- Investments will create more than 12,000 new jobs: 1,000 at Roche and more than 11,000 in support of new US manufacturing capabilities
- Roche already has a significant existing US presence with more than 25,000 employees, 15 R&D centres and 13 manufacturing sites